Testosterone ( DrugBank: Testosterone )
8 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 1 | Spinal and bulbar muscular atrophy | 1 |
| 2 | Amyotrophic lateral sclerosis | 1 |
| 3 | Spinal muscular atrophy | 1 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 5 |
| 60 | Aplastic anemia | 2 |
| 76 | Pituitary gonadotropin secretion hyperthyroidism | 1 |
| 78 | Hypopituitarism | 2 |
| 113 | Muscular dystrophy | 3 |
1. Spinal and bulbar muscular atrophy
Clinical trials : 18 / Drugs : 15 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 17
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00004771 (ClinicalTrials.gov) | October 1992 | 24/2/2000 | Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease | Spinal Muscular Atrophy;Amyotrophic Lateral Sclerosis;Spinobulbar Muscular Atrophy | Drug: leuprolide;Drug: testosterone | National Center for Research Resources (NCRR) | Ohio State University | Completed | 18 Years | N/A | Male | 40 | Phase 2 | NULL |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00004771 (ClinicalTrials.gov) | October 1992 | 24/2/2000 | Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease | Spinal Muscular Atrophy;Amyotrophic Lateral Sclerosis;Spinobulbar Muscular Atrophy | Drug: leuprolide;Drug: testosterone | National Center for Research Resources (NCRR) | Ohio State University | Completed | 18 Years | N/A | Male | 40 | Phase 2 | NULL |
3. Spinal muscular atrophy
Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00004771 (ClinicalTrials.gov) | October 1992 | 24/2/2000 | Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease | Spinal Muscular Atrophy;Amyotrophic Lateral Sclerosis;Spinobulbar Muscular Atrophy | Drug: leuprolide;Drug: testosterone | National Center for Research Resources (NCRR) | Ohio State University | Completed | 18 Years | N/A | Male | 40 | Phase 2 | NULL |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03910738 (ClinicalTrials.gov) | October 29, 2019 | 1/4/2019 | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection;Drug: Placebo 4 mL Solution for Injection;Procedure: MRI;Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities;Behavioral: Assessment of disability | University Hospital, Strasbourg, France | Bayer;Fédération Hospitalo-Universitaire NEUROGENYCS | Recruiting | 18 Years | 55 Years | Male | 40 | Phase 2 | France |
| 2 | NCT03000127 (ClinicalTrials.gov) | July 1, 2018 | 17/12/2016 | Testosterone for Fatigue in Men With MS | A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis | Multiple Sclerosis | Drug: AndroGel 1 % Topical Gel;Drug: Placebos | University of California, Los Angeles | Washington University School of Medicine | Withdrawn | 18 Years | 60 Years | Male | 0 | Phase 2 | United States |
| 3 | NCT02317263 (ClinicalTrials.gov) | December 2014 | 3/12/2014 | A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis | Multiple Sclerosis | Drug: testosterone;Drug: placebo gel | University of California, Los Angeles | NULL | Withdrawn | 18 Years | 60 Years | Male | 0 | Phase 2 | NULL | |
| 4 | NCT01516554 (ClinicalTrials.gov) | February 2012 | 19/1/2012 | Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients | A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients | Multiple Sclerosis;Fatigue | Drug: Testosterone undecanoate;Drug: placebo | Health Sciences Centre, Winnipeg, Manitoba | University of Manitoba;Consortium of Multiple Sclerosis Centers;Manitoba Medical Service Foundation | Terminated | 18 Years | 65 Years | Male | 3 | Phase 2 | Canada |
| 5 | NCT00405353 (ClinicalTrials.gov) | April 2002 | 28/11/2006 | Testosterone Treatment for Multiple Sclerosis | Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial | Multiple Sclerosis | Drug: Androgel 10 grams of gel containing 100 mg of testosterone | University of California, Los Angeles | National Multiple Sclerosis Society | Completed | 18 Years | 65 Years | Male | 10 | Phase 1/Phase 2 | United States |
60. Aplastic anemia
Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR1900002832 | 2015-07-01 | 2019-12-13 | A Multi-centre Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia | A Multi-centrer Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia | Aplstic Anemia | Control group:Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D);Experimental group:Pai-Neng-Da Capsule + Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D); | Jinhua people's Hospital | NULL | Completed | Both | Control group:50;Experimental group:50; | NULL | |||
| 2 | ChiCTR1900028153 | 2015-07-01 | 2019-12-13 | A Multi-centre Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia | A Multi-centrer Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia | Aplstic Anemia | Experimental group:Pai-Neng-Da Capsule + Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D);Control group:Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D); | Jinhua people's Hospital | NULL | Completed | Both | Experimental group:50;Control group:50; | Phase 2-3 | NULL |
76. Pituitary gonadotropin secretion hyperthyroidism
Clinical trials : 29 / Drugs : 44 - (DrugBank : 14) / Drug target genes : 5 - Drug target pathways : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100047299 | 2020-12-01 | 2021-06-12 | The use of morning urinary gonadotropins and sexual hormones in the diagnosis and monitoring treatment of central precocious puberty | The use of morning urinary gonadotropins and sexual hormones in the diagnosis and monitoring treatment of central precocious puberty | precocious puberty | Gold Standard:gonadotropin releasing hormone stimulation test ;Index test:luteinizing hormone, follicle stimulating hormone, estradiol, prolactin, progesterone, testosterone, and human chorionic gonadotropin; | The Children's Hospital, Zhejiang University School of Medicine | NULL | Recruiting | 3 | 10 | Female | Target condition:200;Difficult condition:100 | China |
78. Hypopituitarism
Clinical trials : 492 / Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00080483 (ClinicalTrials.gov) | March 2004 | 5/4/2004 | Testosterone and Growth Hormone for Bone Loss in Men | Will Testosterone and Growth Hormone Improve Bone Structure? | Hypopituitarism;Hypogonadism;Growth Hormone Deficiency | Drug: Testosterone plus somatropin;Drug: testosterone | University of Pennsylvania | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | 18 Years | N/A | Male | 35 | Phase 2 | United States |
| 2 | NCT00144391 (ClinicalTrials.gov) | July 2003 | 1/9/2005 | Testosterone Gel Applied to Women With Pituitary Gland Problems | Physiologic Testosterone Replacement in Women With Hypopituitarism | Panhypopituitarism | Drug: Transdermal Testosterone gel | Charles Drew University of Medicine and Science | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | 18 Years | 55 Years | Female | 20 | Phase 4 | United States |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03123913 (ClinicalTrials.gov) | December 18, 2017 | 12/4/2017 | Study of Testosterone and rHGH in FSHD | Study of Testosterone and rHGH in FSHD (STARFISH): A Proof-of-Concept Study | Facioscapulohumeral Muscular Dystrophy | Drug: Testosterone Enanthate;Drug: Somatropin | University of Rochester | NULL | Completed | 18 Years | 65 Years | Male | 20 | Phase 1 | United States |
| 2 | EUCTR2015-003195-68-GB (EUCTR) | 11/11/2015 | 26/10/2015 | Testosterone therapy in DMD | Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne Muscular Dystrophy. - Testosterone therapy in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy MedDRA version: 18.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Sustanon 250 Product Name: Sustanon 250 Product Code: PRD2175434 INN or Proposed INN: testosterone propionate INN or Proposed INN: testosterone phenylpropionate INN or Proposed INN: testosterone isocaproate INN or Proposed INN: testosterone decanoate | The Newcastle upon Tyne NHS Hospitals Foundation Trust | NULL | Not Recruiting | Female: no Male: yes | 20 | Phase 3 | United Kingdom | ||
| 3 | NCT02571205 (ClinicalTrials.gov) | November 2015 | 24/8/2015 | Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy | Observational Study of Clinical Outcomes for Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: Sustanon (testosterone) | Newcastle-upon-Tyne Hospitals NHS Trust | NULL | Completed | 12 Years | 17 Years | Male | 15 | United Kingdom |